Muthu Veeraputhiran

Associate Professor

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

10 h-index 56 pubs 355 cited

Research Areas

Links

Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dr. Muthu Veeraputhiran's research focuses on the outcomes and treatment of hematologic malignancies, particularly B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). His work investigates the efficacy of advanced therapies such as brexucabtagene autoleucel, a form of CAR T-cell therapy, in relapsed or refractory patient populations. He has examined factors impacting treatment success, including prior treatment regimens and central nervous system responses.

Dr. Veeraputhiran also studies complications and management strategies for conditions like immune effector cell-associated HLH-like syndrome and chronic graft-versus-host disease, exploring combination therapies such as belumosudil and ruxolitinib. His publications include reviews of increasingly recognized clinical entities and real-world data analyses from collaborative research groups.

With a background in Internal Medicine and specialized fellowships in Transfusion Medicine, Hematology, Oncology, and Bone Marrow Transplantation, Dr. Veeraputhiran brings a multidisciplinary approach to his clinical and research endeavors. He is a member of several key professional organizations in hematology and oncology, underscoring his engagement within the field.

Research Overview

Dr. Muthu Veeraputhiran is a physician in the University of Arkansas for Medical Sciences (UAMS) Department of Internal Medicine. Dr. Veeraputhiran received his medical degree from the Stanley Medical College in his native India. He went on to receive a Masters of Public health from the University of Oklahoma. He then completed residency training in Internal Medicine at Abington Memorial Hospital in Pennsylvania. He has also completed fellowships in Transfusion Medicine at UAMS, Hematology, Oncology, and Bone Marrow Transplantation at Wayne State University, and Bone Marrow Transplantation at Stanford University. Dr. Veeraputhiran is board certified in Clinical Cardiac Electrophysiology from the American Board of Internal Medicine. He is a member of several professional organizations, including the American Society for Blood and Marrow Transplantation, the American Association for Blood Banks, the American Board of Internal Medicine, the American Society of Hematology, and the American Society of Oncology.

Metrics

h-index: 10
Publications: 56
Citations: 355

Selected Publications

Real-World Experience with Narsoplimab (OMS721) for the Treatment of Transplant-Associated Thrombotic Microangiopathy (2024) DOI
Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care (2024) DOI
Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease (2023) DOI
Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023) DOI
Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023) DOI
The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2023) DOI
Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study (2023) DOI
Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) (2023) DOI
The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2023) DOI
Interdigitating Dendritic Cell Sarcoma and Indeterminate Dendritic Cell Tumor: Patient Characteristics, Prognostic Factors, and Survival Outcomes for Rare Dendritic Cell Neoplasms (2023) DOI
Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity (2023) DOI
Sleep-wake Disturbance following Allogeneic Hematopoietic Stem Cell Transplantation: Trajectory and Correlates (2023) DOI
Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients (2022) DOI
Is heart rate in post-hematopoietic stem cell transplant patients clinically relevant? (2021) DOI
Intravascular Large B-Cell Lymphoma: A Diagnostic Dilemma (2021) DOI

Grants & Funding

Benton County REACH Covid Health Literacy DHHS - Office of Minority Health - Pass Through: Benton County Government Principal Investigator
No FP attached Kadmon Corporation, LLC Principal Investigator
No FP attached NIH/Nat. Cancer Institute - Pass Through: Alliance for Clinical Trials in Oncology Principal Investigator
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (VIALE-T) AbbVie Inc Principal Investigator
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease Cynata Therapeutics Principal Investigator
No FP attached Agios Pharmaceuticals, Inc. Principal Investigator
A Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Belumosudil Plus Corticosteroids vs Placebo Plus Corticosteroids in Participants =12 Years With Newly Diagnosed Chronic Graft-Versus-Host Disease (cGVHD) Sanofi US Services Principal Investigator
GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (239545) Incyte Corporation Principal Investigator